Shiseido
This article was originally published in The Rose Sheet
Executive Summary
Shinzo Maeda to President & CEO, pending shareholder approval at firm's ordinary general meeting and board of directors meeting in June, Shiseido announces Feb. 4. Maeda replaces Morio Ikeda, who will become director and chairman of the board. Shiseido's cosmetic sales increased 3% to $3.6 bil. (¥1=$.009), while toiletries sales dropped 4.7% to $432.7 mil., the Japanese firm reports Jan. 31. In the Americas, sales were flat at $304.4 mil. Shiseido's overall net sales increased 2.7% to $4.5 bil. in the first nine months of the firm's year, while net income jumped 16.1% to $131.3 mil. For the year, however, Shiseido anticipates recording a consolidated net loss of $133.9 mil., compared to earlier predictions of $114.7 mil. profit. Change is due to $186.9 mil. charge related to the implementation of a special early retirement incentive plan...
You may also be interested in...
Shiseido Restructures Cosmetics Unit For “Mega Brand” Development
Shiseido is restructuring its Cosmetics Business division to promote product development and build a "healthy and vital mega brand," the Japanese company announced March 2. The changes will be effective April 1
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.